Trial Profile
A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary) ; Mycophenolate mofetil; Tacrolimus
- Indications Dry age-related macular degeneration
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Astellas Institute for Regenerative Medicine
- 02 Jan 2024 Planned number of patients changed from 18 to 42.
- 02 Jan 2024 Planned End Date changed from 31 Aug 2024 to 31 Dec 2025.
- 02 Jan 2024 Planned primary completion date changed from 31 Aug 2024 to 31 Dec 2025.